ArticleFrontiers in immunology2025
Tumor-infiltrating immune cell signature score reveals prognostic biomarkers and therapeutic targets for colorectal cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Crucial role of telomere maintenance-related genes in survival prediction and subtype identification in colorectal cancer.Frontiers in molecular biosciences · 2026Article
- Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.Human mutation · 2026Review
- Integrating inflammation, nutrition, and artificial intelligence: A new era in colorectal cancer prognostic scoring.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the leading contributors to cancer-related deaths worldwide, with more than 900,000 new diagnoses and related deaths each year. This study aims to explore the prognostic value of tumor-infiltrating immune cell (TIIC)-related genes in CRC, in order to discover new biomarkers and therapeutic targets. Methods: We integrated CRC transcriptome data from public databases to construct and validate a prognostic model and analyzed single-cell RNA sequencing (scRNA-seq) data to classify immune cell subtypes. A suite of computational models was employed to assess TIIC signature scores and to refine the selection of prognostic TIIC-related genes using multiple machine learning techniques-including Random Survival Forest (RSF), LASSO regression, and Cox proportional hazards regression, among others. In addition, pathway enrichment, immune signature difference analyses, and immunotherapy response predictions were performed. Potential biomarkers and therapeutic targets were identified through differential gene analysis, gene set enrichment analysis (GSEA), and copy number variation (CNV) landscape comparisons between high and low TIIC groups. Results: We identified 137 significant TIIC-RNAs within the CRC microenvironment and developed a prognostic model based on five key TIIC-RNAs. This model, which leveraged machine learning methods such as RSF, LASSO, and Cox regression, demonstrated outstanding performance in survival prediction across TCGA-CRC and external validation datasets, outperforming 22 existing prognostic models. Furthermore, the high TIIC score group showed heightened expression of angiogenesis-related genes, whereas the low score group was enriched for immune response-associated genes. The TIIC signature score was significantly correlated with tumor-infiltrating immune cells, various metabolic characteristics, and chromosomal instability, and it effectively predicted immunotherapy response across diverse cancer types. Conclusion: The findings of this study highlighted the promise of the TIIC signature score in forecasting the outcomes for CRC patients. Additionally, it emphasized its utility in predicting the effects of immunotherapy, thereby enhancing our comprehension of the intricacies within the tumor microenvironment. Further research needs to concentrate on assessing the clinical utility of the TIIC signature score while also confirming its relevance across various populations and treatment contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.